



## PRRSV Vaccinology and Immunology

Guest Editors:

**Dr. Hiep Vu**

Nebraska Center for Virology and  
Department of Animal Science,  
University of Nebraska-Lincoln,  
Lincoln, NE 68583, USA

**Prof. Dr. Asit Pattnaik**

School of Veterinary and  
Biomedical Sciences, University  
of Nebraska-Lincoln, Lincoln, NE,  
USA

Deadline for manuscript  
submissions:

**closed (30 June 2021)**

### Message from the Guest Editors

Almost 30 years have elapsed since the first PRRSV strain was successfully isolated and propagated in cell culture. Much has been learned about the virus' biology and pathogenesis, and its interaction with the host. A number of vaccines against PRRSV have been made available. Regional efforts to eradicate the virus from the swine herds have been attempted. Despite this significant progress, PRRSV remains one of the most economically important viral pathogens affecting swine production worldwide.

The scope of this Special Issue focuses on the recent findings on the efficacy of PRRS vaccines under experimental and production conditions, the influence of vaccines on virus transmission and evolution within a swine herd, the host immune response to a wild-type virus infection or vaccination, and the rationale of the design of a new generation of vaccines with improved levels of safety and efficacy.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)